SQZ Biotechnologies Company
SQZ Biotechnologies Company (SQZ) Stock Overview
Explore SQZ Biotechnologies Company’s financial performance, market position, analyst ratings, and future outlook.
SQZ Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of SQZ Biotechnologies Company (SQZ) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.05.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.16 and a market capitalization of 12.8M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Dr. Howard Bernstein M.D., Ph.D.
53
200 Arsenal Yards Boulevard, Watertown, MA
2020